Login or sign up
For business

Eupraxia Pharmaceuticals

4.0· 10 reviews
Average ratingGreat
4.0/ 5

Based on 10 reviews

530%
440%
330%
20%
10%
Ask AI

What reviewers say about Eupraxia Pharmaceuticals

Based on 10 reviews on Trustburn · updated 64 days ago

Customers generally describe the products as reliable, effective, and reasonably priced, while praising the responsive customer service and fast shipping.
What does Eupraxia Pharmaceuticals do?

Eupraxia Pharmaceuticals discovers, develops, and plans to market innovative technologies and drug delivery systems for prevalent diseases through research and collaboration.

Are there any complaints about Eupraxia Pharmaceuticals?

The reviews on file mention a lack of variety in the product range, average service quality, and room for improvement in customer support, shipping, and packaging.

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, through research and development and collaboration of experts within the medical field (both individuals and enterprise), is discovering, developing, and plans to market innovative technologies for some of society’s most prevalent diseases. The company is advancing the development of a wide portfolio of potential drug and drug delivery system opportunities. Eupraxia intends to provide and continue to build value to its shareholders and to society through the development and marketing of its revolutionary drug and drug delivery platform combination developed in cooperation with its joint venture partner. By joining forces with a company that has a successful history of getting drugs to market Eupraxia is increasing value to shareholders by decreasing risk and making the trajectory of getting the drug to patients more linear and faster.